Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) General Information

Description

Portfolio of preclinical assets and allosteric modulator drug discovery platform in Geneva, Switzerland.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Geneva
  • Switzerland
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Neurosterix
Corporate Office
  • Geneva
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform)‘s full profile, request access.

Request a free trial

Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026037949-A1 3-cyclopropylpyrazole derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor Pending 15-Aug-2024
WO-2026037961-A1 3-cyclopropylpyrazole derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor Pending 15-Aug-2024
AU-2023379984-A1 Novel bicyclic[1,2,4]triazolone derivatives as negative allosteric modulators of mglu7 receptors Pending 14-Nov-2022
EP-4619100-A1 Novel bicyclic[1,2,4]triazolone derivatives as negative allosteric modulators of mglu7 receptors Pending 14-Nov-2022
US-20260200911-A1 Novel compounds Pending 14-Nov-2022 C07D471/04
To view Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform)’s complete patent history, request access »

Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform)‘s full profile, request access.

Request a free trial

Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) FAQs

  • Where is Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) headquartered?

    Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) is headquartered in Geneva, Switzerland.

  • What industry is Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) in?

    Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform)’s primary industry is Buildings and Property.

  • Is Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) a private or public company?

    Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) is a Private company.

  • What is Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform)’s current revenue?

    The current revenue for Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) is .

  • Who are Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform)’s investors?

    Addex Therapeutics has invested in Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform).

  • When was Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) acquired?

    Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) was acquired on 02-Apr-2024.

  • Who acquired Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform)?

    Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) was acquired by Neurosterix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process